S&P 5007,340.53▼1.0% Nasdaq24,328.38▼0.7% Dow50,759.42▼1.6% Russell 2K2,701.87▼1.5% 10-Yr5.10%−2bp VIX25.46+2.55 WTI$85.11▼0.7% Gold$3,801.10▼1.4% EUR/USD1.099▼0.0% BTC$62,987▼2.9% Nikkei58,697▼0.3%
At close · Tue, Nov 17, 2026
Daily Market Updates.

US Markets

Home›US Markets›IPOs›Sanofi reviews Insmed acquisition.

Sanofi reviews Insmed acquisition.

Insmed stock rose after report.

Insmed Inc. shares increased following information that Sanofi SA is evaluating a possible takeover. The pharmaceutical giant seeks new growth avenues to lessen dependence on Dupixent. Insmed generates revenue from two respiratory medications: Brinsupri and Arikayce.

Brinsupri reported $400.1 million in third-quarter sales, while Arikayce brought in $124.4 million. Insmed anticipates $1.35 billion to $1.4 billion in Brinsupri revenue and $460 million to $470 million in Arikayce sales for 2026. The company also develops treprostinil palmitil inhalation powder for lung conditions.

More like this

Sources

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.